Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) to market Dutasteride Capsules, 0.5 mg in American market. The drug is used in treating enlarged prostate gland.
According to IMS data, the US market for Dutasteride Capsules is approximately US$ 470 million. “The product has gone off patent on November 20, 2015 and Strides Shasun is amongst the first wave of generic players to receive this approval”, said the company.
The product will be manufactured at the Company’s Oral dosage facility at Bangalore and marketed by Strides Shasun in the US Market.